8.35
+0.61(+7.88%)
Currency In USD
| Previous Close | 7.74 |
| Open | 7.66 |
| Day High | 8.49 |
| Day Low | 7.55 |
| 52-Week High | 11.89 |
| 52-Week Low | 4.44 |
| Volume | 85,130 |
| Average Volume | 110,206 |
| Market Cap | 195.32M |
| PE | -7.52 |
| EPS | -1.11 |
| Moving Average 50 Days | 6.58 |
| Moving Average 200 Days | 6.49 |
| Change | 0.61 |
If you invested $1000 in Nuvectis Pharma, Inc. (NVCT) since IPO date, it would be worth $2,569.23 as of March 14, 2025 at a share price of $8.35. Whereas If you bought $1000 worth of Nuvectis Pharma, Inc. (NVCT) shares 2 years ago, it would be worth $807.54 as of March 14, 2025 at a share price of $8.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
GlobeNewswire Inc.
Mar 04, 2025 1:00 PM GMT
Research conducted at the Lerner Research Institute, Cleveland Clinic (at Case Western Reserve University)Fort Lee, NJ, March 04, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharm
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
GlobeNewswire Inc.
Feb 07, 2025 1:30 PM GMT
FORT LEE, NJ, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical n
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
GlobeNewswire Inc.
Feb 05, 2025 2:01 PM GMT
FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical